Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
stomach cancer
Biotech
Bolt halves workforce again to find cash for cancer drug readout
Bolt has halved its workforce for the second time in two years as the oncology biotech delays a readout of its immunotherapy.
James Waldron
Oct 2, 2025 6:45am
Amgen-Zai stomach cancer asset loses OS benefit in final analysis
Sep 3, 2025 4:33pm
I-Mab buys Bridge Health for $3M to strengthen givastomig push
Jul 17, 2025 8:45am
Amgen, Zai say stomach cancer candidate hits phase 3 mark
Jun 30, 2025 10:36am
CARsgen touts phase 2 stomach cancer win for cell therapy
Jan 2, 2025 10:42am
Roche, EarlySign add AI-powered lung cancer diagnosis to collab
Jul 8, 2022 10:24am